Last updated on October 2017

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.


Brief description of study

The main purpose of this study is evaluation of deep molecular response (MR4.5; BCR-ABL IS < 0.0032%) after 24 months of therapy with nilotinib in newly diagnosed patients with chronic phase CML. Via the use of MR4.5 EUTOS ('European Treatment and Outcome Study for CML') laboratories adequate and reliable molecular monitoring as a key parameter for assessing molecular milestones is fostered. Furthermore this trial aims to investigate early prediction of outcome in newly diagnosed patients with nilotinib by assessing the individual decline of BCR-ABL transcripts. Quality of life will bemeasured via use of the EORTC CML-24 questionnaire.

Clinical Study Identifier: NCT02546674

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novartis Pharmaceuticals

Novartis Investigative Site
Heidenheim, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Mannheim, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Herne, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Luebeck, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Aschaffenburg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Augsburg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Bad Liebenwerda, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Bad Saarow, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Bad Soden, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Baden-Baden, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Bayreuth, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Berlin, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Bremerhaven, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Chemnitz, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Donauwoerth, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Dortmund, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Dresden, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Duesseldorf, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Erfurt, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Essen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Frankfurt, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Georgsmarienhütte, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Gera, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Giessen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Goslar, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Göppingen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Halberstadt, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Hannover, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Heidelberg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Heilbronn, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Hof, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Kassel, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Kiel, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Koeln, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Magdeburg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Muenchen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Muenster, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Mutlangen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Nordhorn, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Nuernberg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Offenburg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Paderborn, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Potsdam, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Rostock, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Saarbruecken, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Saarbrücken, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Schorndorf, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Schweinfurt, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Stolberg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Velbert, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Westerstede, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Wiesbaden, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Wilhelmshaven, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Worms, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Wuerselen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Wuerzburg, Germany
  Connect »